乳酸杆菌CL22菌株治疗Balb/c小鼠Hp感染性胃炎模型的有效性研究

Effect of Bacillus acidi lactici CL22 strain on Helicobacter Pylori infectious gastritis in Balb/c mouse model

目的:观察乳酸杆菌对Balb/c小鼠Hp感染性胃炎的治疗作用,探讨一种非抗生素治疗Hp的可能方式。方法:通过接种Hp,建立Balb/c小鼠Hp感染胃炎动物模型,将造模成功的32只Balb/c小鼠随机分为4组,每组8只:第1组(PPI三联干预治疗组)、第2组(乳酸杆菌CL22处理组)、第3组(乳酸杆菌CL24处理组)、第4组(生理盐水对照组),用相应干扰剂分别连续灌胃治疗10d。另8只正常小鼠为第5组(空白对照组)。最后一次灌胃4周后处死小鼠,HE染色判断小鼠胃黏膜组织学损伤,并用快速尿素酶试验、Giemsa染色和细菌培养进行Hp的检测。结果:5组间胃窦黏膜病理组织学评分比较有统计学差异(F=7.932,P=0.000),其中第1组、第2组、第3组、第5组的胃窦黏膜病理组织学评分均低于第4组(P<0.05),第1组、第2组、第5组两两比较差异无统计学意义(P>0.05),第3组与第5组比较差异有显著性(P<0.05);胃体黏膜病理组织学评分5组比较有统计学差异(F=6.241,P=0.001),其中第1组、第2组、第3组、第5组的胃体黏膜病理组织学评分均低于第4组(P<0.05),第1组、第2组、第3组、第5组两两比较差异无统计学意义(P>0.05)。胃窦部Hp根除率5组间比较有统计学差异(χ2=16.923,P=0.002),其中第1组、第2组明显高于第4组(P<0.05),第3组与第4组比较,无统计学差异(P>0.05);胃体部Hp根除率5组间比较有统计学差异(χ2=14.295,P=0.006),其中第1组、第2组明显高于第4组(P<0.05),第3组与第4组比较,无统计学差异(P>0.05)。结论:乳酸杆菌CL22菌株可有效抑杀Balb/c小鼠Hp感染性胃炎模型体内Hp,疗效与PPI+抗生素相当,可以成为非抗生素治疗Hp的又一选择。

Objective To observe the therapeutic effect of Bacillus acidi lactici on Helicobacter Pylori （Hp） infectious gastritis in Balb/c mouse model so as to explore a possible non-antibiotic treatment for lip. Methods To establish a Balb/c mouse model with Hp infectious gastritis through inoculation of mankind Hp, 32 Balb/c mice infected by Hp were randomly divided into 4 groups： Group 1 （PPI trigeminy treatment group ）, Group 2 （Bacillus acidi lactici CL22 treatment group ）, Group 3 （ Bacillus acidi lactici CL24 treatment group ） , and Group 4 （ normal saline control group ）.Intragastric administration was given continuously for 10 days. Another 8 normal mice were chosen as Group 5 （ blank control group ）. All mice were killed after 4 weeks since last intragastric administration. Hp was detected by rapid urease test, Giemsa dying, and bacterial culture, and histopathologic changes in the gastric mucosa of mice were determined by H-E staining. Results There were significant differences in pathohistologic scores in sinus ventriculi among the 5 groups （F = 7.932, P=0.000）. The scores in Group 1 , Group 2, Group 3 ,and Group 5 were obviously lower than those in Group 4 （ P 〈 0.05 ） , but there were not significant differences among Group 1 , 2, and 5 （ P 〉 0.05 ）. The pathohistologic score in Group 3 was obviously higher than that in Group 5 （ P 〈 0.05 ）. There were significant differences in pathohistologic scores in corpus ventriculi among the 5 groups （F=6. 241, P =0. 001 ）. The scores in Group 1 , Group 2, Group 3 , and Group 5 were obviously lower than those in Group 4 （ P 〈 0.05 ） , but there were not significant differences among Group 1 , 2, 3 , and 5 （ P 〉 0.05 ）. There was significant difference in Hp eradication rates in sinus ventriculi among the 5 groups（χ^2= 16. 923 ,P =0. 002）. The Hp eradication rates in Group 1 and 2 were obviously lower than those in Group 4 （ P 〈 0.05 ） , but there was not significant difference between Group 1 and Group 2, Group 3 and Group 4 （ P 〉 0.05 ）. There also were significant differences in Hp eradication rate in corpus ventriculi among the 5 groups （ χ^2 = 14. 295 , P = 0. 006） . Of them, Group 1 and Group 2 were higher than Group 4 （ P 〈 0.05 ） , but there were not obviously differences between Group 1 and 2, Group 3 and 4 （ P 〉 0.05 ）. Conclusion Bacillus acidi lactici strain CL22 can effectively inhibit and eradicate Hp in Balb/c mouse model with Hp infectious gastritis in vivo. The therapeutic effect of Bacillus acidi lactici strain CL22 is equal to PPI ＋ antibiotics and could be another choice of non-antibiotic treatment for Hp.